Startups
Health

Christiana Care scientists make colon cancer discovery

The Helen F. Graham Cancer & Research Institute’s findings may lead to new treatment options.

A potential new breakthrough for colon cancer has been discovered in Delaware. (Photo by Flickr user Michael (a.k.a. moik) McCullough, used under a Creative Commons license)

A recent study led by Bruce Boman of Christiana Care Health System, found that colon cancer stem cell activity may be inhibited by retinoic acid signaling. Retinoic acid, a vitamin A–derived molecule often found in topical anti-aging products (Retin-A), is used in cancer treatment due to its affect on cell development.

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. It can be difficult to treat due to drug resistance; this discovery may help oncologists target these cancers with more success.

“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” Dr. Boman said.

The paper, published in the Oct. 5 issue of Oncotarget, is co-authored by former University of Delaware student researcher Shirin Modarai (who currently works for Christiana Care), among others.

Read the findings
Companies: ChristianaCare
Engagement

Join the conversation!

Find news, events, jobs and people who share your interests on Technical.ly's open community Slack

Trending

Delaware daily roundup: Delmarva Power vendor stats; DelDOT's $15M federal grant; 50 best companies to work for

Delaware daily roundup: Over 4,000 Black-owned businesses uncovered; Dover makes rising cities list; a push for online sports betting

Delaware daily roundup: Ladybug Fest illuminates small biz; Hahnemann Hospital's biotech future; intl. politics and a Middletown project

Wilmington businesses light up for Ladybug Festival 2024, featuring bands from around the globe

Technically Media